This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, M., Merry, S., Smith, J. et al. Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16. Br J Cancer 57, 576–578 (1988). https://doi.org/10.1038/bjc.1988.131
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.131
This article is cited by
-
Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin
Cancer Chemotherapy and Pharmacology (1994)
-
Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes
Cancer Chemotherapy and Pharmacology (1991)
-
Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil
Blut (1990)